Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

42.9%

3 terminated/withdrawn out of 7 trials

Success Rate

57.1%

-29.4% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2

5(71.4%)

Phase 3

1(14.3%)

Phase 1

1(14.3%)

7Total

Phase 2(5)

Phase 3(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT05905783Phase 3Terminated

Hidradenitis Suppurativa Study of Izokibep

Role: lead

NCT05683496Phase 1Completed

Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED)

Role: lead

NCT05355805Phase 2Completed

Hidradenitis Suppurativa Phase 2b Study of Izokibep

Role: lead

NCT05623345Phase 2Terminated

Psoriatic Arthritis Study of Izokibep

Role: lead

NCT05384249Phase 2Terminated

Phase 2b Pivotal Study of Izokibep in Non-infectious, Intermediate-, Posterior- or Pan-uveitis

Role: lead

NCT04706741Phase 2Completed

A Trial of the Efficacy and Safety of Izokibep in the Treatment of Non-anterior Uveitis

Role: lead

NCT04713072Phase 2Completed

A Study to Investigate Efficacy, Tolerability and Safety of ABY-035 in Patients With Active Psoriatic Arthritis

Role: lead

All 7 trials loaded